Nov. 25, 2014, 12:59 PM
- The merger between Cocrystal Pharma (OTCQB:COCP +10.9%) and RFS Pharma, LLC has closed. The shareholders of each company will each own ~50% of combined entity.
- The merged organization will have a broad pipeline of products in hepatitis, influenza, rhinovirus, dengue fever and norovirus.
- Dr. Gary Wilcox will be CEO and Co-Chairman of the new firm. RFS Founder and Chairman Dr. Raymond F. Schinazi will be the other Co-Chairman.
COCP vs. ETF Alternatives
Cocrystal is a biotechnology company which develops novel medicines for use in the treatment of human viral diseases. Cocrystal has developed proprietary structure-based drug design technology and antiviral nucleoside chemistry to create first-in-class and best-in-class antiviral drug... More
Other News & PR